Understanding the Effects of NOAC Combined with Antiplatelet Therapy on Clot Kinetics

Diana A. Gorog

doi:10.1055/s-0039-1696645

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2020; 120(01): 008-010
DOI: 10.1055/s-0039-1696645

Invited Editorial Focus

Georg Thieme Verlag KG Stuttgart · New York

Understanding the Effects of NOAC Combined with Antiplatelet Therapy on Clot Kinetics

Authors

Diana A. Gorog

¹National Heart and Lung Institute, Imperial College London, London, United Kingdom

²Postgraduate Medical School, University of Hertfordshire, Hatfield, United Kingdom

Abstract

Volltext

Referenzen

References
1 Lip GYH, Collet J-PP, Haude M. , et al; ESC Scientific Document Group. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace 2019; 21 (02) 192-193
2 Sumaya W, Geisler T, Kristensen SD, Storey RF. Dual antiplatelet or dual antithrombotic therapy for secondary prevention in high-risk patients with stable coronary artery disease?. Thromb Haemost 2019; 19 (10) 1583-1589
3 Franchi F, Rollini F, Garcia E. , et al. Effects of edoxaban on the cellular and protein phase of coagulation in patients on dual antiplatelet therapy. Thromb Haemost 2019; 120 (02) 83-93
4 Dias JD, Norem K, Doorneweerd DD, Thurer RL, Popovsky MA, Omert LA. Use of thromboelastography (TEG) for detection of new oral anticoagulants. Arch Pathol Lab Med 2015; 139 (05) 665-673
5 Bliden KP, Chaudhary R, Mohammed N. , et al. Determination of non-vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. J Thromb Thrombolysis 2017; 43 (04) 437-445
6 Dinkelaar J, Patiwael S, Harenberg J, Leyte A, Brinkman HJ. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin Chem Lab Med 2014; 52 (11) 1615-1623
7 Lau YC, Xiong Q, Shantsila E, Lip GY, Blann AD. Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation. J Thromb Thrombolysis 2016; 42 (04) 535-544
8 Spinthakis N, Gue Y, Farag M. , et al. Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation. EP Europace 2019; 21 (09) 1297-1306
9 Franchi F, Rollini F, Cho JR. , et al. Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. Thromb Haemost 2016; 115 (03) 622-631
10 Hoffman M, Monroe DM. Impact of non-vitamin K antagonist oral anticoagulants from a basic science perspective. Arterioscler Thromb Vasc Biol 2017; 37 (10) 1812-1818
11 Borst O, Münzer P, Alnaggar N. , et al. Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. Blood Adv 2018; 2 (06) 715-730
12 Szczeklik A, Dropinski J, Radwan J, Krzanowski M. Persistent generation of thrombin after acute myocardial infarction. Arterioscler Thromb 1992; 12 (05) 548-553
13 Ardissino D, Merlini PA, Bauer KA. , et al. Coagulation activation and long-term outcome in acute coronary syndromes. Blood 2003; 102 (08) 2731-2735
14 Loeffen R, Godschalk TC, van Oerle R. , et al. The hypercoagulable profile of patients with stent thrombosis. Heart 2015; 101 (14) 1126-1132
15 Mega JL, Braunwald E, Wiviott SD. , et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (01) 9-19
16 Eikelboom JW, Connolly SJ, Bosch J. , et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14) 1319-1330
17 Zeymer U, Schrage B, Westermann D. Dual pathway inhibition with low-dose direct factor Xa inhibition after acute coronary syndromes-why is it not used in clinical practice?. Thromb Haemost 2018; 118 (09) 1528-1534
18 Gorog DA, Fayad ZA, Fuster V. Arterial thrombus stability: does it matter and can we detect it?. J Am Coll Cardiol 2017; 70 (16) 2036-2047
19 Shaya SA, Saldanha LJ, Vaezzadeh N, Zhou J, Ni R, Gross PL. Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. J Thromb Haemost 2016; 14 (01) 143-152
20 Semeraro F, Incampo F, Ammollo CT. , et al. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation. Thromb Res 2016; 138: 22-29
21 Ammollo CT, Semeraro F, Incampo F, Semeraro N, Colucci M. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2010; 8 (04) 790-798
22 Farag M, Niespialowska-Steuden M, Okafor O. , et al. Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation. Platelets 2016; 27 (07) 687-693
23 Panova-Noeva M, Schulz A, Spronk HM. , et al. Clinical determinants of thrombin generation measured in presence and absence of platelets-results from the Gutenberg Health Study. Thromb Haemost 2018; 118 (05) 873-882
24 Trabold K, Makhoul S, Gambaryan S, van Ryn J, Walter U, Jurk K. The direct thrombin inhibitors dabigatran and lepirudin inhibit GPIbα-mediated platelet aggregation. Thromb Haemost 2019; 119 (06) 916-929
25 Kirchhof P, Benussi S, Kotecha D. , et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
26 Neumann F-JJ, Sousa-Uva M, Ahlsson A. , et al; ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019; 40 (02) 87-165
27 Proietti M, Mujovic N, Potpara TS. Optimizing stroke and bleeding risk assessment in patients with atrial fibrillation: a balance of evidence, practicality and precision. Thromb Haemost 2018; 118 (12) 2014-2017
28 Borre ED, Goode A, Raitz G. , et al. Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost 2018; 118 (12) 2171-2187
29 Capodanno D, Greco A. Risk stratification for bleeding in the elderly with acute coronary syndrome: not so simple. Thromb Haemost 2018; 118 (06) 949-952
30 Sibbing D, Angiolillo DJ, Huber K. Antithrombotic therapy for acute coronary syndrome: past, present and future. Thromb Haemost 2017; 117 (07) 1240-1248